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Several studies have been conducted to establish the phenomenon of vaccine-drug
interaction against various categories of chemotherapeutic agents, such as fluoroquino-
lones and chloramphenicol (1). They can either increase or decrease the phagocytic func-
tion or modulate the immune response triggered by an antigen (2). Investigations have
revealed that chloroquine prophylaxis for malaria is associated with an impaired anti-
body response to rabies vaccine administered intradermally (3). It was proposed that chlo-
roquine might interfere with the antigen processing mechanism and T-cell recognition
(4, 5). In addition, chloroquine raises pH within lysosomes and thus interferes with the
fusion of viral and lysosomal membranes, which is necessary to release viral nucleo-
capsid. It has been also shown that chloroquine interferes with secretion of interleukin-1
(IL-1) by monocytes, inhibiting the generation of immunoglobulin secretary lymphocy-
tes (4). However, chloroquine did not affect the antibody response of yellow fever vac-
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Immune suppression resulting from chemoprophylaxis
and potential drug interaction were investigated in ex-
perimental animals pre-medicated with ampicillin and
chloroquine followed by immunization with bovine se-
rum albumin bearing liposomes prepared by the reverse
phase evaporation method. The prepared liposomes were
evaluated for particle size, entrapment efficiency and in
vitro release. Humoral immune response was measured
in terms of systemic IgG antibody titre by the ELISAme-
thod. The present study showed that 7:3 molar ratio of
soya phosphatidylcholine and cholesterol produced lipo-
somes of mean diameter of 235.4 ± 10.3 nm and entrap-
ment efficiency of 41.3 ± 3.2%. Ampicillin significantly
(p < 0.05) decreased the antibody titre whereas chloroquine
did not reduce the antibody titre significantly. The study
will help in programming a new drug management and
in characterization of vaccine-drug interaction.
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cine (6). Hence, the antigens showed different immune response profiles in dependance
on antigen types; therefore, the interaction of drugs with the immune response after im-
munization would be different. For many of these agents, the underlying mechanisms of
immunomodulation are not well defined and some events are strongly dependent on
the method applied. However, studies on immunomodulation by antibiotics are still in
infancy and the methods applicable for its assessment are continually improving. On the
other hand, vesicular systems are better than traditional vaccine adjuvants. Immunolog-
ical adjuvants such as Freund’s complete and incomplete adjuvant, bacterial endotoxins,
polyanions, mineral adsorbents (inducing local or systemic toxicity) form unacceptable
granulomas or may lack efficiency (7). The use of vesicular systems like liposomes as
carriers of peptides, proteins and DNA vaccines require simple, easy to scale up techno-
logy, capable of high yield vaccine entrapment (8). It is well known that controlled re-
lease of antigens is the only way of achieving a long-lasting boosting effect. Studies have
revealed that liposomes entrapping bovine serum albumin enhanced systemic and mu-
cosal immune response following oral administration of liposomes (9). It was found that
rapid targeting of massive doses of antigenic material to antigen presenting cells (APCs),
especially macrophages, have, however, often been the principal source of liposomal
adjuvanticity (10). Although many research methodologies have been applied so far to
elucidate the mechanism of immunomodulation by chemotherapeutic agents, no concise
conclusion has been drawn due to antigenic variation. Hence, in the present investiga-
tion, a protein antigen, BSA (bovine serum albumin), was encapsulated in a vesicular
system (liposomes) and the effect of ampicillin and chloroquine (selected as the model
drugs) on the humoral immune response was evaluated. In the present work, an effort
has been made to provide an inexpensive and sensitive method for the preliminary
screening of chemotherapeutic agents for their immunomodulating activity.
EXPERIMENTAL
Materials
Bovine serum albumin (BSA) and cholesterol AR (CH) were purchased from the Cen-
tral Drug House, New Delhi, India. Soya phosphatidylcholine (SPC) and Sephadex G-150
were purchased from Sigma (USA). Ampicillin (1 g vial) and chloroquine (Resochin in-
jection, 40 g L–1, 30-mL vial) were purchased from Zydus Cadila and Bayer Pharmaceu-
ticals, India, respectively. ELISA kit (Specific anti-rat IgG) was purchased from Gennei,
India. All other chemicals used were of analytical grade.
Methods
Preparation of liposomes. – Liposomes were prepared by the reverse phase evapora-
tion technique (11). Briefly, SPC and CH (mol L–1) were dissolved in 5-mL of diethyl ether
(organic phase) in a glass boiling tube, to which 2-mL of aqueous phase, phosphate-bu-
ffer saline (PBS, 10 mmol L–1, pH 7.4) containing BSA (1 g L–1) was added. The mixture
was sonicated (Soniweld, India) for 5 min at 4 °C and was attached to a rotary evapora-
tor to dry the contents at 37 °C under vacuum (250 mm Hg) until a gel was formed. Vac-
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uum was released and the tube was removed from the evaporator and subjected to vig-
orous mechanical agitation on a vortex mixer for 5 min. When the gel collapsed to fluid,
it was again fitted to the rotary flash evaporator for removal of the organic solvent. After
10 min drying and 5 min vortexing, this was repeated twice again. The final liposomal
suspension was subjected to complete removal of the last traces of organic solvent in the
rotary flash evaporator under vacuum (600 mm Hg) for 15 min. To this emulsion, 3 mL
of PBS (pH 7.4) was added to hydrate the mixture, resulting in formation of large unila-
mellar vesicles. The resulting large unilamellar vesicles were passed 5 times through 0.45-
-and 10 times through 0.2-mm polycarbonate membrane (MDI, India).
Determination of vesicle size. – The mean diameter of liposomes was measured by
photon correlation spectroscopy with an autosize II C apparatus (Malvern Instruments,
UK) in PBS (pH 7.4).
Entrapment efficiency. – About 0.2 mL of liposomes was eluted with PBS (pH 7.4)
through Sephadex G-150 minicolumn to separate unentrapped antigen (12). The method
was repeated thrice with a fresh syringe packed with gel each time. The fraction was fi-
nally collected free from unentrapped antigen. To the vesicular fraction, a minimum
amount of Triton X-100 (0.5%, m/V) was added to disrupt the vesicles. The liberated an-
tigen was estimated by using the BCA (bicinchoninic acid) protein assay at 562 nm and
percent antigen entrapment was calculated (13). Liposome recovery was 95.3 ± 2.2%.
In vitro release of the antigen. – In vitro drug release profile of the antigen was studied
using the dialysis technique (14). First, the liposomal formulation was centrifuged at
12857 ´ g for 2 minutes through Sephadex G-150 column to remove unentrapped drug.
Subsequently, 2.0 mL of liposomal suspension (without unentrapped antigen) was taken
into a dialysis tube (Sigma) and placed in a beaker containing 10 mL of PBS (pH 7.4).
The beaker was placed over a magnetic stirrer, and the temperature of the assembly was
maintained at 37 ± 1 °C throughout the study. Samples were withdrawn at predetermi-
ned time intervals (2, 4, 6, 8, 10, 12, 24 and 48 h) and replaced with PBS (pH 7.4) to mi-
mic infinite sink conditions. The process was repeated thrice and the samples were ana-
lyzed for BSA at 562 nm (13).
Stability study on storage. – The ability of vesicles to retain the antigen was assessed
by keeping the liposomal suspension in sealed vials (10 mL capacity) after flushing with
nitrogen at 4 ± 0.5, 25 ± 0.5 and 37 ± 0.5 °C for one month under controlled conditions
and then evaluated for their size and leaked percent of encapsulated BSA using BCA at
562 nm. The initial antigen content was considered as 100%.
Medication and immunization. – In vivo studies were carried out as per guidelines
compiled by CPCSEA (Committee for the Purpose of Control and Supervision of Experi-
ments on Animals), Ministry of Culture, Government of India. The Institutional Animal
Ethics Committee approved the study. Male albino rats (Wistar strain, 80 ± 20 g) were
maintained at standard laboratory chow and water ad libitum in a temperature and light
controlled environment at the Hindu College of Pharmacy (Sonepat, Haryana, India).
Animals were divided into seven groups of six animals each. Ampicillin and chloroquine
were injected i.m. as per the therapeutic dose-dosage regimen based on the body mass of
rats (Table III). Simultaneously, ampicillin and chloroquine-treated rats were immunized
subcutaneously with a single dose of 100-mg equivalent of BSA-loaded liposomes as the
100-mg of BSA encapsulated in vesicular system induced significantly higher antibody ti-
tre than the equivalent amount of BSA emulsified in Freund’s complete adjuvant (14).
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Immunization was done after pre-medication of albino rats with ampicillin and chlo-
roquine (Table III) applying three variables – following medication (FM), after seven
days of medication (ASDM) and during medication (DM). The immune response of BSA-
-loaded liposomes (without medication) was regarded as the control (CONTR) group.
Determination of IgG titre by ELISA. – Specific anti-BSA antibody level in the serum
was determined by ELISA (15). Each well of the flat-bottomed polystyrene plates was
coated with 100-mL of BSA (1 mg L–1 in 0.02 mol L–1 Tris/HCl, pH 9.0) and incubated
overnight at 4 °C. Thereafter, the wells were washed ten times with PBS-Tween buffer
(0.02 mol L–1 Tris, 0.05 % V/V Tween 20, pH 7.4) and to each well, 100-mL of the diluted
serum sample was added and incubated for 2 h at room temperature. The plates were
washed three times with PBS-Tween buffer and 100-mL of diluted horseradish-peroxida-
se-conjugated anti-globulin-specific anti-rat IgG was added to each well and incubated
for 2 h. The plates were again washed three times with PBS-Tween buffer and 100-mL of
substrate solution 3,3’,5,5’-tetramethyl benzidine containing hydrogen peroxide was
added to each well. The plates were incubated in dark at room temperature for 15 min.
The reaction was stopped by adding 50-mL of 2 mol L–1 H2SO4 to each well and the absor-
bance was measured at 450 nm using a microplate ELISA reader (Lab System Multiscan,
Finland). The immune response was shown in terms of reciprocal end point dilution.
Statistical analysis. – The results were expressed as mean ± standard deviation. Sta-
tistical analysis was carried out using the one-way ANOVA and two-way ANOVA tests.
All statistical calculations were performed with the GRAPH PAD Prism 4.01 software.
RESULTS AND DISCUSSION
Preparation and characterization of vesicular system
The present study was performed to evaluate the effect of ampicillin and chloro-
quine prophylaxis on the humoral immune response elicited by bovine serum albumin
encapsulated in liposomes, acting as an efficient carrier for delivery of proteins and pep-
tides (8). Liposomes were prepared using the reverse phase evaporation technique, asso-
ciated with relatively higher encapsulation efficiency of macromolecules such as anti-
gens and peptides (11). The nature of the buffer used to dissolve the antigen with respect
to composition; pH and molarity did not interfere with liposome formation or the yield
of entrapment (8). The prepared vesicular system was characterized for particle size, en-
trapment efficiency, in vitro release and storage stability profile. The particle size of lipo-
somal formulation was measured by photon correlation microscopy. On the basis of en-
trapment efficiency and particle size, different molar ratios of SPC and CH were taken
for the preparation of liposomes (Table I). It was observed that formulation LPS-3 (7:3
mol L–1, SPC and CH) produced liposomes of 235.4 ± 10.3 nm mean diameter with maxi-
mum entrapment efficiency of 41.3 ± 3.2% of antigen. Hence, the data of liposomal for-
mulations justified the results reported earlier in which the optimized liposomal formu-
lation was used for vaccination (14). Besides, 7:3 mol L–1 of phospholipid and cholesterol
produced size-controlled vesicles using the hydration method followed by sonication (16).
Hence, the optimized formulation LPS-3 was then considered for in vitro release experi-
mentation and storage stability study. Data of the in vitro release study indicated that
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4.3% of BSA was released from the vesicular system (liposomes) after 8 h in phosphate
buffer saline (pH 7.4). However, only 11.1% of BSA was released over 48 h, exhibiting
fast initial release, followed by slow release (Fig. 1). Slow release of the entrapped anti-
gen could be due to the large molecular size of the antigen (69,000 D) with poor
diffusitivity through the vesicular membrane. However, the small amount of antigen re-
leased quickly at the initial stage might be attributed to the surface adsorbed antigen.
Moreover, cholesterol affects profoundly the liposomal membrane properties. Incorpora-
tion of cholesterol in the gel-state bi-layer can induce continuous and permanent transi-
tion to an ordered liquid crystalline state, which contributes to slow release characteris-
tics. Further, stability (in the process as well as in storage) is very important especially in
the case of immunological products since denaturation or deactivated antigen will lead
to generation of an insufficient immune response, making the subject prone to the dis-
ease against which the immunization is being carried out. In storage at 4 ± 0.5, 25 ± 0.5
and 37 ± 0.5 °C for 30 days, it was observed that around 6.8% of antigen was leaked from
optimized formulation LPS-3 stored at 4 ± 0.5 °C compared to 11.1 and 19.9% of that
stored at 25 ± 0.5 and 37 ± 0.5 °C, respectively (Table II). A non-significant difference in
vesicle size was observed in formulation LPS-3 stored at 4 ± 0.5 °C. Hence, the formula-
tion stored at 4 ± 0.5 °C demonstrated a very low antigen leakage compared to the for-
mulation stored at 25 ± 0.5 °C and 37 ± 0.5 °C, respectively, suggesting that refrigerated
conditions are well suited to the developed formulation. It was demonstrated previously
in a long-term storage stability study that liposomes were stable for over 1 year (17).
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LPS-1 9:1 29.5 ± 2.3 221.3 ± 11.6
LPS-2 8:2 35.4 ± 4.1 230.5 ± 9.8
LPS-3 7:3 41.3 ± 3.2 235.4 ± 10.3
LPS-4 6:4 34.2 ± 3.6 236.6 ± 15.4
LPS-5 5:5 32.3 ± 3.2 240.2 ± 9.5
























Fig. 1. In vitro release profile of BSA
from the liposomal (LPS-3) formula-
tion (mean ± SD, n = 3).
Systemic IgG response
We have investigated the effect of ampicillin and chloroquine on the humoral im-
mune response in albino rats triggered by bovine serum albumin entrapped liposomes.
The optimized formulation (LPS-3) was used for vaccination of animals. The specific anti-
-rat IgG antibody titre was measured after 21 days in all medicated and control groups
(after immunization) by the ELISA technique and the results were expressed as recipro-
cal end point dilution.
Effect of ampicillin on IgG antibody titre
In vivo study indicated that ampicillin in therapeutic dose-dosage regimen signifi-
cantly (p < 0.05) reduced the antibody titre compared to the control group (Fig. 2). As we
immunized the rats at the time of ampicillin prophylaxis, it was observed that ampicillin
markedly reduced the antibody titre in two groups of animals, in the following medica-
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Table II. Study of storage stability of the BSA-loaded liposomal (LPS-3) formulation
Parameter
Storage temperature (°C)
4 ± 0.5 25 ± 0.5 37 ± 0.5
Residual BSA (%)a 93.2 ± 4.1 89.9 ± 4.6 80.1 ± 3.1
Vesicle size (nm)a 245.4 ± 4.6 305.8 ± 8.5 410.5 ± 7.8
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Fig. 2. Effect of ampicillin and chloroquine on the specific antirat IgG antibody titre (mean ± SD, n = 6).
tion and during medication groups of rats, and not in the third group, after 7 days of
medication, indicating the immunosuppressive effect of ampicillin. However, the absence
of immunosuppression in the after-7-days-of-medication group clearly indicated that the
drug was completely excreted and did not interact with immune cells to modulate the
immune response. The results are concomitant with the similar structurally related drug,
amoxycillin, which impaired antibody titre in rat pups immunized with oval albumin
(18). In addition, researchers also categorize ampicillin as an immunodepressing antibi-
otic (19).
Effect of chloroquine on IgG antibody titre
Experimental data of in vivo study indicated that chloroquine did not reduce the an-
tibody titre significantly in the three groups of rats, following medication, during medi-
cation and after 7 days of medication, compared to the control group (Fig. 2). Hence, the
data suggest that chloroquine did not interfere with the immune mechanism, as did am-
picillin. In contrast, chloroquine (10–4 mol L–1, plateau plasma chloroquine level) sup-
pressed the immune response either by interfering with virus replication or macrophage
function required for antibody synthesis (5, 6). However, the chloroquine base (300 mg
base weekly regimen; 10–7 mol L–1 plateau plasma chloroquine level) was found inade-
quate to suppress immune response triggered by Yellow fever vaccine (20). Bovine se-
rum albumin is a model antigenic protein and the mechanism earlier proposed for chlo-
roquine immunomodulation does not affect the anti-BSA antibody titre. Hence, it is
necessary to check the individual antigen with chloroquine to explore the phenomena of
vaccine-drug interaction.
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Groups prepared for administration of the
drug and BSA bearing liposomes
Ampicillin 8.3 mg kg–1 5 days Following medication (rats were medi-
cated for 5 days and then immunized)
(i.m.) During medication (rats were medicated
for 2.5 days, then immunized and medi-
cated again for the following 2.5 days)
After 7 days of medication (rats were
medicated for 5 days, then left to rest for
7 days and then immunized)
Chloroquine 10 mg kg–1
for first 8 h,
followed by
15 mg kg–1 at
16 h and 24 h
(i.m.)
3 days Following medication (rats were medi-
cated for 3 days and then immunized)
During medication (rats were medicated
for 1.5 days, then immunized and medi-
cated again for 1.5 days)
After 7 days of medication (rats were
medicated for 3 days, then left to rest for
7 days and then immunized)
BSA (in liposomes) 100-mg (s.c.) Single dose Control group
CONCLUSIONS
In conclusion, the antigen encapsulated in liposomes induced the humoral immune
response. The results indicate that ampicillin produced a significant reduction in the an-
tibody titre (p < 0.05) as compared to the control group when administered in the thera-
peutic dose-dosage regimen, whereas chloroquine did not decrease the antibody titre
significantly.
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S A @ E T A K
U~inak ampicilina i klorokina na humoralnu imuno{ku reakciju
na gove|i albumin kapsuliran u liposome
JITENDER MADAN, DINESH KAUSHIK, SATISH SARDANA, DINA NATH MISHRA,
SHALINDER KUMAR SINGH i BINOD KUMAR SINGHSNET
Na eksperimentalnim `ivotinjama koje su prvo tretirane ampicilinom i klorokinom
a zatim imunizirane gove|im serumskim albuminom s liposomima pra}ena je supresija
imunolo{kog sustava i potencijalna interakcija lijekova. Liposomi su pripravljeni meto-
dom reverzno-fazne evaporacije, a odre|ena im je veli~ina ~estica, koli~ina supstancije
koju mogu inkorporirati i osloba|anje in vitro. Humoralna imunolo{ka reakcija pra}ena
je odre|ivanjem titra IgG antitijela ELISA metodom. Rezultati rada pokazuju da lipo-
somi s fosfatidilkolinom iz soje i kolesterolom u molnom omjeru 7:3 imaju prosje~ni pro-
mjer 235.4 ± 10.3 nm i sposobnost inkorporacije 41.3 ± 3.2%. Ampicilin je zna~ajno (p < 0.05)
smanjio titar antitijela, a klorokin nije. Ovi }e rezultati biti korisni u programiranju no-
vog re`ima primjene lijekova i u pra}enju interakcije izme|u cjepiva i lijeka.
Klju~ne rije~i: imunomodulacija, liposomi, gove|i albumin, ampicilin, klorokin
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